ADC Therapeutics Reports Q3 Sales and Presents ZYNLONTA Clinical Data
What happened
ADC Therapeutics reported preliminary third-quarter sales of approximately $21 million and stated its cash runway extends into 2029. The company presented new lymphoma data for its cancer drug ZYNLONTA at the American Society of Hematology meeting. In the phase Ib LOTIS-7 study, ZYNLONTA combined with glofitamab achieved an overall response rate of 88.7% among 97 patients with relapsed or refractory DLBCL.
From themarketsdaily.com
Why it matters
The presentation of positive clinical results for ZYNLONTA, which is currently approved for diffuse large B-cell lymphoma, suggests plans to expand its use into earlier treatment settings and other lymphomas. The reported sales figures provide insight into the commercial performance of the drug.
From themarketsdaily.com
Who's involved
- ADC TherapeuticsPresented clinical data and reported Q3 sales for ZYNLONTA.
- American Society of HematologyOrganized the meeting where ADC Therapeutics presented its findings.
- Mohamed ZakiServes as Chief Medical Officer for ADC Therapeutics.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- ADC TherapeuticsSpeculative
The presentation of strong clinical data and positive Q3 sales might materially boost ADC Therapeutics' market position and revenue outlook.
- Nxera PharmaSpeculative
Nxera Pharma might see its competitive position strengthened against Robert S. Negrin's organization due to the positive clinical data and sales figures.
Keep exploring
The entities involved
-
ADC Therapeutics
company in Épalinges, Switzerland
-
American Society of Hematology
organization